Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis.

Emicizumab prophylaxis significantly reduces bleeding episodes in patients with hemophilia A (PwHA). There is little information on coagulant potentials in emicizumab-treated PwHA with infection, however. We encountered an emicizumab-treated PwHA with inhibitor, complicated with Epstein-Barr virus-associated infectious mononucleosis (IM) in phase 1/2 study (ACE001JP/ACE002JP). Although it was a typical clinical course of IM, activated partial thromboplastin time was mildly prolonged but rotational thromboelastometry revealed severely impaired coagulant potential. The blood concentration of emicizumab decreased moderately in the low concentration range, resulting in an increased risk of bleeding and possibly leading to severe ileocecal bleeds requiring coil embolization. The blood concentrations of factors IX/X little decreased and antiemicizumab antibodies did not develop, however. After the influence by IM resolved, his coagulant potentials gradually recovered with the recovery of emicizumab concentration, and parameters by global coagulation assays improved. An IM case for emicizumab-treated PwHA may need to monitor using global coagulation assays.

[1]  S. Chebon,et al.  Low immunogenicity of emicizumab in persons with haemophilia A , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  Y. Yoshimura,et al.  Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A , 2021, Journal of thrombosis and haemostasis : JTH.

[3]  F. Jonsson,et al.  Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII , 2021, Clinical Pharmacokinetics.

[4]  M. Gobbi,et al.  Characterization of the neutralizing anti‐emicizumab antibody in a patient with hemophilia A and inhibitor , 2020, Journal of thrombosis and haemostasis : JTH.

[5]  N. Frey,et al.  Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A , 2020, Clinical Pharmacokinetics.

[6]  K. Nogami,et al.  Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors , 2020, British journal of haematology.

[7]  J. Oldenburg,et al.  A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. , 2019, Blood.

[8]  A. Ishiguro,et al.  A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  K. Nogami,et al.  Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis , 2019, International Journal of Hematology.

[10]  C. Hermans,et al.  Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. , 2019, The Lancet. Haematology.

[11]  K. Nogami,et al.  New therapies using nonfactor products for patients with hemophilia and inhibitors. , 2019, Blood.

[12]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.

[13]  K. Nogami,et al.  Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti‐idiotype monoclonal antibodies , 2018, Journal of thrombosis and haemostasis : JTH.

[14]  Tomoko Matsumoto,et al.  Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab , 2018, Journal of thrombosis and haemostasis : JTH.

[15]  A. Lienhart,et al.  Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab , 2018, Haematologica.

[16]  Tetsuji Sato,et al.  Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. , 2017, Blood advances.

[17]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[18]  M. Cataldi,et al.  Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes , 2017, International journal of molecular sciences.

[19]  V. Jiménez‐Yuste,et al.  The burden of inhibitors in haemophilia patients , 2016, Thrombosis and Haemostasis.

[20]  K. Nogami.  The utility of thromboelastography in inherited and acquired bleeding disorders , 2016, British journal of haematology.

[21]  Tetsuji Sato,et al.  Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.

[22]  K. Yoneyama,et al.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. , 2016, Blood.

[23]  M. Shieh,et al.  111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma , 2015, Oncotarget.

[24]  Yasuyoshi Watanabe,et al.  64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients , 2015, EJNMMI Research.

[25]  M. Shima,et al.  Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation , 2014, Journal of thrombosis and haemostasis : JTH.

[26]  T. Igawa,et al.  Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity , 2013, PloS one.

[27]  R. Ljung,et al.  Factor VIII products and inhibitor development in severe hemophilia A. , 2013, The New England journal of medicine.

[28]  Tsukasa Suzuki,et al.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.

[29]  D. Lewandowski,et al.  Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[31]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[32]  G. Zampighi,et al.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. , 1981, Biochemistry.

[33]  A. Tiede.  Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia , 2017, Hämostaseologie.